Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy

Clin Infect Dis. 2008 Oct 15;47(8):1105-8. doi: 10.1086/592116.

Abstract

In this crossover study of ezetimibe monotherapy in 48 antiretroviral-treated patients with human immunodeficiency virus infection, the mean changes in low-density lipoprotein cholesterol were -5.3% (-11 mg/dL) and +5.5% (+4 mg/dL) with ezetimibe treatment and placebo, respectively (P = .04). Ezetimibe was safe and effective in reducing low-density lipoprotein cholesterol and is an option for patients who cannot tolerate treatment with a statin.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / pharmacology*
  • Antiretroviral Therapy, Highly Active / adverse effects*
  • Azetidines / pharmacology*
  • Cholesterol, LDL / blood*
  • Ezetimibe
  • Female
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • Humans
  • Hypercholesterolemia / chemically induced*
  • Male
  • Middle Aged
  • Placebos / administration & dosage

Substances

  • Anti-HIV Agents
  • Azetidines
  • Cholesterol, LDL
  • Placebos
  • Ezetimibe